BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-823@pharmaconomics
DTSTAMP:20260707T033835Z
DTSTART;VALUE=DATE:20260331
DTEND;VALUE=DATE:20260401
SUMMARY:BHVN Phase 2 — BHV-1400
DESCRIPTION:Phase 2 trial results for BHV-1400 in IgA Nephropathy are due Mar 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1935979/000193597926000022/a2025q4bhvnearningsprex991.htm\n\nTrack it: https://pharmaconomics.com/e/823
URL:https://pharmaconomics.com/e/823
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:BHVN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR